Edition:
United States

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

8.66USD
13 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$8.66
Open
$9.35
Day's High
$9.35
Day's Low
$8.40
Volume
28,113
Avg. Vol
28,946
52-wk High
$27.06
52-wk Low
$3.61

Latest Key Developments (Source: Significant Developments)

Galmed Pharmaceuticals Reports Q3 Loss Per Share $0.05
Monday, 5 Nov 2018 07:00am EST 

Nov 5 (Reuters) - Galmed Pharmaceuticals Ltd ::GALMED PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.05.Q3 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $1.5 MILLION VERSUS $300,000.Q3 REVENUE VIEW $142,000 -- THOMSON REUTERS I/B/E/S.SAYS PLANNING TO INITIATE ARMOR, PHASE 3 PIVOTAL STUDY OF ARAMCHOL AT END OF Q2 OF 2019.  Full Article

Galmed Pharmaceuticals Announces Pricing Of $6 Mln Registered Direct Offering
Tuesday, 3 Apr 2018 07:00am EDT 

April 3 (Reuters) - Galmed Pharmaceuticals Ltd ::ANNOUNCES PRICING OF $6.0 MILLION REGISTERED DIRECT OFFERING.ENTERED INTO SECURITIES PURCHASE AGREEMENT WITH BIOTECHNOLOGY VALUE FUND, L.P. AND CERTAIN OF ITS AFFILIATES.DEAL TO BUY, SELL 1 MILLION SHARES, WARRANTS TO PURCHASE 1 MILLION SHARES, FOR $6.00/SHARE, RELATED WARRANT.  Full Article

Galmed Announces Arrive Study Data
Wednesday, 14 Feb 2018 07:12am EST 

Feb 14 (Reuters) - Galmed Pharmaceuticals Ltd ::GALMED ANNOUNCES ARRIVE STUDY DATA.TOP-LINE RESULTS FROM ARRIVE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT.ANNOUNCED TOP-LINE RESULTS FROM ARRIVE TRIAL, WHICH DID NOT MEET ITS PRIMARY ENDPOINT.TOPLINE DATA FROM GALMED'S PHASE IIB ARREST STUDY IS EXPECTED IN Q2 2018.  Full Article

Israeli Tax Authority Issues Tax Ruling On Galmed Pharma's Unit
Wednesday, 7 Feb 2018 09:27am EST 

Feb 7 (Reuters) - Galmed Pharmaceuticals Ltd ::GALMED PHARMACEUTICALS -ISRAELI TAX AUTHORITY ISSUED TAX RULING GRANTING CO'S UNIT "PREFERRED TECHNOLOGICAL ENTERPRISE" STATUS, SUBJECT TO CONDITIONS.GALMED PHARMACEUTICALS - GRANT OF "PREFERRED TECHNOLOGICAL ENTERPRISE" STATUS MEANS UNIT TO BE SUBJECT TO REDUCED ISRAELI CORPORATE TAX RATE.GALMED PHARMACEUTICALS - TAX RULING APPLIES FOR 5 YRS UNTIL 2022, MAY BE EXTENDED FURTHER SUBJECT TO MEETING SOME REQUIREMENTS - SEC FILING.  Full Article

683 Capital Management Llc Reports 5.1 Pct Passive Stake In Galmed Pharmaceuticals Ltd As Of Dec 6
Monday, 18 Dec 2017 05:26pm EST 

Dec 18 (Reuters) - Galmed Pharmaceuticals Ltd ::683 CAPITAL MANAGEMENT LLC REPORTS 5.1 PERCENT PASSIVE STAKE IN GALMED PHARMACEUTICALS LTD AS OF DEC 6 - SEC FILING.  Full Article

Galmed Pharmaceuticals Q3 loss per share $0.23
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Galmed Pharmaceuticals Ltd :Galmed Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.23.Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.Q3 revenue $300,000 versus I/B/E/S view $319,000.Galmed Pharmaceuticals - ‍cash, cash equivalents,marketable securities totaled $9.0 million as of Sept 30, compared to $15.5 million at December 31, 2016​.Galmed Pharmaceuticals Ltd - ‍Galmed believes that its cash balance will be sufficient to maintain its current operations through 2018​.  Full Article

Galmed Pharmaceuticals announces pricing of offering to existing investors, members of board
Thursday, 3 Aug 2017 04:52pm EDT 

Aug 3 (Reuters) - Galmed Pharmaceuticals Ltd :Galmed Pharmaceuticals announces pricing of offering of ordinary shares to existing investors and members of the board of directors.Galmed Pharmaceuticals - ‍entered into agreement for a registered direct offering of 332,038 ordinary shares at a price of $7.10 per share​.Galmed Pharmaceuticals expects to receive gross proceeds of about $2.7 million​.  Full Article

Galmed Pharmaceuticals reports Q2 loss per share of $0.22
Monday, 31 Jul 2017 06:00am EDT 

July 31 (Reuters) - Galmed Pharmaceuticals Ltd :Galmed Pharmaceuticals reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.22.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Q2 revenue $300,000 versus I/B/E/S view $358,000.‍Cash, cash equivalents,marketable securities totaled $9.1 million as of June 30, 2017, compared to $15.5 million at December 31, 2016​.  Full Article

Galmed Pharma Q1 loss per share $0.26
Monday, 15 May 2017 08:00am EDT 

May 15 (Reuters) - Galmed Pharmaceuticals Ltd :Galmed pharmaceuticals reports first quarter 2017 financial results.Q1 loss per share $0.26.Q1 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.Q1 revenue $300,000 versus i/b/e/s view $258,000.Galmed pharmaceuticals - continues to believe that its cash balance will be sufficient to maintain its current operations through first half of 2018.  Full Article

Therapix Biosciences names Josh Blacher CFO
Wednesday, 3 May 2017 08:30am EDT 

May 3 (Reuters) - Therapix Biosciences Ltd ::Therapix Biosciences announces the appointment of Josh Blacher as chief financial officer.Prior to joining Therapix, Blacher served as Chief Financial Officer at Galmed Pharmaceuticals.  Full Article